News
The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...
The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...
According to the Financial Times, MSD – known as Merck & Co in the US and Canada – is in the final stages of a $10 billion ...
Whether stemming from early childhood adversity, combat exposure, or interpersonal abuse, trauma leaves long-term imprints on ...
Improving efficiencies and uncomplicating processes are critical to the future success of NHS Trusts across the country. The ...
Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...
Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results